{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:29:42Z","timestamp":1787509782657,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Grant-in-Aid for Scientific Research","award":["21K07804"],"award-info":[{"award-number":["21K07804"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s12185-025-04098-7","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T05:12:29Z","timestamp":1762837949000},"page":"321-331","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Emicizumab enhances the ex vivo coagulant potential in plasma samples from patients with von Willebrand disease"],"prefix":"10.1007","volume":"123","author":[{"given":"Mutsumi","family":"Yabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9348-9815","authenticated-orcid":false,"given":"Masahiro","family":"Takeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Sasai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruto","family":"Shimonishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Ogiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"4098_CR1","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1111\/j.1538-7836.2006.02146.x","volume":"4","author":"JE Sadler","year":"2006","unstructured":"Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand factor. J Thromb Haemost. 2006;4:2103\u201314.","journal-title":"J Thromb Haemost"},{"key":"4098_CR2","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/nm.2942","volume":"18","author":"T Kitazawa","year":"2012","unstructured":"Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012;18:1570\u20134.","journal-title":"Nat Med"},{"key":"4098_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057479","volume":"8","author":"Z Sampei","year":"2013","unstructured":"Sampei Z, Igawa T, Soeda T, Okuyama-Nishida Y, Moriyama C, Wakabayashi T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS ONE. 2013;8:e57479.","journal-title":"PLoS ONE"},{"key":"4098_CR4","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","volume":"374","author":"M Shima","year":"2016","unstructured":"Shima M, Hanabusa H, Taki M, Matsushita T, Sato T, Fukutake K, et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016;374:2044\u201353.","journal-title":"N Engl J Med"},{"key":"4098_CR5","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1703068","volume":"377","author":"J Oldenburg","year":"2017","unstructured":"Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377:809\u201318.","journal-title":"N Engl J Med"},{"key":"4098_CR6","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1182\/blood.2019001869","volume":"134","author":"G Young","year":"2019","unstructured":"Young G, Liesner R, Chang T, Sidonio R, Oldenburg J, Jimenez-Yuste V, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134:2127\u201338.","journal-title":"Blood"},{"key":"4098_CR7","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/NEJMoa1803550","volume":"379","author":"J Mahlangu","year":"2018","unstructured":"Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379:811\u201322.","journal-title":"N Engl J Med"},{"key":"4098_CR8","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","volume":"6","author":"SW Pipe","year":"2019","unstructured":"Pipe SW, Shima M, Lehle M, Shapiro A, Chebon S, Fukutake K, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019;6:e295\u2013305.","journal-title":"Lancet Haematol"},{"key":"4098_CR9","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1182\/bloodadvances.2017006684","volume":"1","author":"M Shima","year":"2017","unstructured":"Shima M, Hanabusa H, Taki M, Matsushita T, Sato T, Fukutake K, et al. Long-term safety and efficacy of emicizumab in a phase 1\/2 study in patients with hemophilia A with or without inhibitors. Blood Adv. 2017;1:1891\u20139.","journal-title":"Blood Adv"},{"key":"4098_CR10","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1111\/jth.14022","volume":"16","author":"K Nogami","year":"2018","unstructured":"Nogami K, Matsumoto T, Tabuchi Y, Soeda T, Arai N, Kitazawa T, et al. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa\/factor X bispecific antibody emicizumab. J Thromb Haemost. 2018;16:1078\u201388.","journal-title":"J Thromb Haemost"},{"key":"4098_CR11","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/bjh.16574","volume":"190","author":"S Furukawa","year":"2020","unstructured":"Furukawa S, Nogami K, Shimonishi N, Nakajima Y, Matsumoto T, Shima M. Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis-treated haemophilia A patients with inhibitors. Br J Haematol. 2020;190:727\u201335.","journal-title":"Br J Haematol"},{"key":"4098_CR12","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1007\/s12185-021-03095-w","volume":"113","author":"K Mizumachi","year":"2021","unstructured":"Mizumachi K, Tsumura Y, Nakajima Y, Koh K, Nogami K. Clot waveform analysis for perioperative hemostatic monitoring of arthroscopic synovectomy in a pediatric patient with hemophilia A and inhibitor receiving emicizumab prophylaxis. Int J Hematol. 2021;113:930\u20135.","journal-title":"Int J Hematol"},{"key":"4098_CR13","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1111\/jth.14746","volume":"18","author":"M Takeyama","year":"2020","unstructured":"Takeyama M, Nogami K, Matsumoto T, Noguchi-Sasaki M, Kitazawa T, Shima M. An anti-factor IXa\/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A. J Thromb Haemost. 2020;18:825\u201333.","journal-title":"J Thromb Haemost"},{"key":"4098_CR14","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s12185-020-02959-x","volume":"112","author":"K Ogiwara","year":"2020","unstructured":"Ogiwara K, Nogami K, Matsumoto N, Noguchi-Sasaki M, Hirata M, Soeda T, et al. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa\/X. Int J Hematol. 2020;112:621\u201330.","journal-title":"Int J Hematol"},{"key":"4098_CR15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s12185-021-03276-7","volume":"115","author":"Y Nakajima","year":"2022","unstructured":"Nakajima Y, Mizumachi K, Shimonishi N, Furukawa S, Yada K, Ogiwara K, et al. Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients. Int J Hematol. 2022;115:489\u201398.","journal-title":"Int J Hematol"},{"key":"4098_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s12185-019-02698-8","volume":"110","author":"K Yada","year":"2019","unstructured":"Yada K, Nogami K, Ogiwara K, Shida Y, Furukawa S, Yaoi H, et al. Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis. Int J Hematol. 2019;110:419\u201330.","journal-title":"Int J Hematol"},{"key":"4098_CR17","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1055\/s-0041-1725009","volume":"121","author":"M Takeyama","year":"2021","unstructured":"Takeyama M, Furukawa S, Yada K, Ogiwara K, Shimonishi N, Nakajima Y, et al. Ex vivo prediction of comprehensive coagulation potential using simulated blood concentrations of emicizumab in patients with acquired hemophilia A. Thromb Haemost. 2021;121:1289\u201398.","journal-title":"Thromb Haemost"},{"key":"4098_CR18","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1055\/s-0040-1716542","volume":"121","author":"H Yaoi","year":"2021","unstructured":"Yaoi H, Shida Y, Kitazawa T, Shima M, Nogami K. Emicizumab augments thrombus formation in whole blood from patients with hemophilia A under high shear flow conditions. Thromb Haemost. 2021;121:279\u201386.","journal-title":"Thromb Haemost"},{"key":"4098_CR19","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1111\/hae.14272","volume":"27","author":"H Yaoi","year":"2021","unstructured":"Yaoi H, Shida Y, Kitazawa T, Shima M, Nogami K. Emicizumab improves thrombus formation of type 2A von willebrand disease under high shear condition. Haemophilia. 2021;27:e194\u2013203.","journal-title":"Haemophilia"},{"key":"4098_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.thromres.2020.11.026","volume":"198","author":"H Yaoi","year":"2021","unstructured":"Yaoi H, Shida Y, Kitazawa T, Shima M, Nogami K. Activated factor VIII-mimicking effect by emicizumab on thrombus formation in type 2N von Willebrand disease under high shear flow conditions. Thromb Res. 2021;198:7\u201316.","journal-title":"Thromb Res"},{"key":"4098_CR21","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/hae.14581","volume":"28","author":"H Yaoi","year":"2022","unstructured":"Yaoi H, Shida Y, Ogiwara K, Kitazawa T, Shima M, Nogami K. Emicizumab enhances thrombus formation in vitro under high shear flow conditions in whole blood from patients with type 1 and type 3 von Willebrand disease. Haemophilia. 2022;28:694\u2013701.","journal-title":"Haemophilia"},{"key":"4098_CR22","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1182\/bloodadvances.2019000656","volume":"3","author":"AC Weyand","year":"2019","unstructured":"Weyand AC, Flood VH, Shavit JA, Pipe SW. Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies. Blood Adv. 2019;3:2748\u201350.","journal-title":"Blood Adv"},{"key":"4098_CR23","doi-asserted-by":"publisher","first-page":"e495","DOI":"10.1111\/hae.14209","volume":"27","author":"MG Cefalo","year":"2021","unstructured":"Cefalo MG, Ronco F, Di Felice G, Rinelli M, Oriana V, Massoud M, et al. Effectiveness of emicizumab in preventing life-threatening bleeding complications in type 3 von Willebrand disease with inhibitors: a paediatric report. Haemophilia. 2021;27:e495\u20137.","journal-title":"Haemophilia"},{"key":"4098_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/hae.14450","volume":"28","author":"VM Thomas","year":"2022","unstructured":"Thomas VM, Abou-Ismail MY, Lim MY. Off-label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: a scoping review of the literature. Haemophilia. 2022;28:4\u201317.","journal-title":"Haemophilia"},{"key":"4098_CR25","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/hae.14491","volume":"28","author":"C Shanmukhaiah","year":"2022","unstructured":"Shanmukhaiah C, Jijina F, Kannan S, Pai NG, Kulkarni B, Khuba SV, et al. Efficacy of emicizumab in von Willebrand disease (VWD) patients with and without alloantibodies to von Willebrand factor (VWF): report of two cases and review of literature. Haemophilia. 2022;28:286\u201391.","journal-title":"Haemophilia"},{"key":"4098_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2020.102530","volume":"87","author":"AA Barg","year":"2021","unstructured":"Barg AA, Avishai E, Budnik I, Brutman TB, Tamarin I, Dardik R, et al. The potential role of emicizumab prophylaxis in severe von Willebrand disease. Blood Cells Mol Dis. 2021;87:102530.","journal-title":"Blood Cells Mol Dis"},{"key":"4098_CR27","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/MBC.0000000000001298","volume":"35","author":"FI LeMaistre","year":"2024","unstructured":"LeMaistre FI, Chiang E, Streiff MB, Yui JC. Efficacy of emicizumab therapy in two adult patients with type 3 von Willebrand disease. Blood Coagul Fibrinolysis. 2024;35:206\u20138.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"4098_CR28","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/jha2.984","volume":"5","author":"A Briane","year":"2024","unstructured":"Briane A, Horvais V, Sigaud M, Trossa\u00ebrt M, Drillaud N, Ternisien C, et al. Bleeding management in type 3 von Willebrand disease with anti-von Willebrand factor inhibitor: a literature review and case report. EJHaem. 2024;5:964\u201370.","journal-title":"EJHaem"},{"key":"4098_CR29","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1021\/bi00507a028","volume":"20","author":"LT Mimms","year":"1981","unstructured":"Mimms LT, Zampighi G, Nozaki Y, Tanford C, Reynolds JA. Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside. Biochemistry. 1981;20:833\u201340.","journal-title":"Biochemistry"},{"issue":"2","key":"4098_CR30","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/jth.12474","volume":"12","author":"A Muto","year":"2014","unstructured":"Muto A, Yoshihashi K, Takeda M, Kitazawa T, Soeda T, Igawa T, et al. Anti-factor IXa\/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost. 2014;12(2):206\u201313.","journal-title":"J Thromb Haemost"},{"key":"4098_CR31","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/978-1-4939-7196-1_20","volume":"1646","author":"E Duncan","year":"2017","unstructured":"Duncan E, Rodgers S. One-Stage Factor VIII Assays. Methods Mol Biol. 2017;1646:247\u201363.","journal-title":"Methods Mol Biol"},{"issue":"Suppl 1","key":"4098_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/ijlh.12345","volume":"37","author":"JC Roberts","year":"2015","unstructured":"Roberts JC, Flood VH. Laboratory diagnosis of von Willebrand disease. Int J Lab Hematol. 2015;37(Suppl 1):11\u20137.","journal-title":"Int J Lab Hematol"},{"key":"4098_CR33","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1182\/bloodadvances.2020003265","volume":"5","author":"PD James","year":"2021","unstructured":"James PD, Connell NT, Ameer B, Di Paola J, Eikenboom J, Giraud N, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021;5:280\u2013300.","journal-title":"Blood Adv"},{"key":"4098_CR34","doi-asserted-by":"publisher","first-page":"e427","DOI":"10.1111\/hae.13266","volume":"23","author":"T Matsumoto","year":"2017","unstructured":"Matsumoto T, Nogami K, Tabuchi Y, Yada K, Ogiwara K, Kurono H, et al. Clot waveform analysis using CS-2000i distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A. Haemophilia. 2017;23:e427\u201335.","journal-title":"Haemophilia"},{"key":"4098_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29731","volume":"69","author":"M Takeyama","year":"2022","unstructured":"Takeyama M, Furukawa S, Onishi T, Noguchi-Sasaki M, Shima M, Nogami K. Heterogeneous coagulant potential of emicizumab in neonatal factor VIII-deficient plasma. Pediatr Blood Cancer. 2022;69:e29731.","journal-title":"Pediatr Blood Cancer"},{"key":"4098_CR36","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/jth.12987","volume":"13","author":"S Furukawa","year":"2015","unstructured":"Furukawa S, Nogami K, Ogiwara K, Yada K, Minami H, Shima M. Systematic monitoring of hemostatic management in hemophilia A patients with inhibitor in the perioperative period using rotational thromboelastometry. J Thromb Haemost. 2015;13:1279\u201384.","journal-title":"J Thromb Haemost"},{"key":"4098_CR37","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3390\/diagnostics10020118","volume":"10","author":"J Hartmann","year":"2020","unstructured":"Hartmann J, Murphy M, Dias JD. Viscoelastic hemostatic assays: moving from the laboratory to the site of care-a review of established and emerging technologies. Diagnostics (Basel). 2020;10:118.","journal-title":"Diagnostics (Basel)"},{"key":"4098_CR38","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1182\/blood.2020008501","volume":"137","author":"CV Denis","year":"2021","unstructured":"Denis CV, Susen S, Lenting PJ. Von Willebrand disease: what does the future hold? Blood. 2021;137:2299\u2013306.","journal-title":"Blood"},{"key":"4098_CR39","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1182\/bloodadvances.2018017418","volume":"2","author":"M Lavin","year":"2018","unstructured":"Lavin M, Aguila S, Dalton N, Nolan M, Byrne M, Ryan K, et al. Significant gynecological bleeding in women with low von Willebrand factor levels. Blood Adv. 2018;2:1784\u201391.","journal-title":"Blood Adv"},{"key":"4098_CR40","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1046\/j.1365-2516.2000.00447.x","volume":"6","author":"PA Kouides","year":"2000","unstructured":"Kouides PA, Phatak PD, Burkart P, Braggins C, Cox C, Bernstein Z, et al. Gynaecological and obstetrical morbidity in women with type I von Willebrand disease: results of a patient survey. Haemophilia. 2000;6:643\u20138.","journal-title":"Haemophilia"},{"key":"4098_CR41","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/ejh.13250","volume":"103","author":"G Castaman","year":"2019","unstructured":"Castaman G, James PD. Pregnancy and delivery in women with von Willebrand disease. Eur J Haematol. 2019;103:73\u20139.","journal-title":"Eur J Haematol"},{"key":"4098_CR42","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1055\/s-0040-1710315","volume":"120","author":"Y Nakajima","year":"2020","unstructured":"Nakajima Y, Nogami K, Yada K, Furukawa S, Noguchi-Sasaki M, Hirata M, et al. Emicizumab improves ex vivo clotting function in patients with mild\/moderate hemophilia A. Thromb Haemost. 2020;120:968\u201376.","journal-title":"Thromb Haemost"},{"key":"4098_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30590","volume":"70","author":"M Takeyama","year":"2023","unstructured":"Takeyama M, Matsumoto N, Abe H, Harada S, Ogiwara K, Furukawa S, et al. Coagulant potentials of emicizumab in the plasmas from infant and toddler patients with hemophilia A. Pediatr Blood Cancer. 2023;70:e30590.","journal-title":"Pediatr Blood Cancer"},{"key":"4098_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9010189","author":"M Ranucci","year":"2020","unstructured":"Ranucci M, Baryshnikova E. Sensitivity of viscoelastic tests to platelet function. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9010189.","journal-title":"J Clin Med"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04098-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04098-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04098-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:01:49Z","timestamp":1772892109000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04098-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4098"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04098-7","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.Y. and K.S. declare no conflicts of interest. S.F. has received personal fees from Takeda Pharmaceutical Co., CSL Behring, Chugai Pharmaceutical Co., Ltd., and Sanofi S.A. M.T. has received honoraria from CSL Behring, Sanofi K.K., Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., Fujimoto Pharmaceutical Corporation, and Bayer Yakuhin Ltd.; research funding from Chugai Pharmaceutical Co., Ltd. and Japan Blood Products Organization; and has participated in advisory boards for Chugai Pharmaceutical Co., Ltd. and Sanofi K.K. N.S. teaches a course supported by CSL Behring. Y.N. has received personal fees from Chugai Pharmaceutical Co., Ltd., and grants from Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., and KM Biologics Co. K.O. has received personal fees from Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Sanofi S.A., and CSL Behring. K.N. has received personal fees, grants, and non-financial support from Chugai Pharmaceutical Co., Ltd.; personal fees from F. Hoffmann-La Roche Ltd.; personal fees and grants from SEKISUI MEDICAL, Sysmex Co., Takeda Pharmaceutical Co., Ltd., CSL Behring Co., Sanofi S.A., Bayer AG, KM Biologics Co., Novo Nordisk A\/S, and Fujimoto Seiyaku; is a member of the IJH Editorial Board and holds patents related to emicizumab.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}